Logotype for Mink Therapeutics Inc

Mink Therapeutics (INKT) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Mink Therapeutics Inc

Proxy filing summary

1 May, 2026

Executive summary

  • Annual meeting scheduled for June 17, 2026, to be held virtually, with voting available online, by phone, mail, or during the meeting.

  • Stockholders as of April 23, 2026, are eligible to vote on director elections and auditor ratification.

  • Proxy materials are distributed via internet access, with options for printed copies and electronic delivery to reduce environmental impact.

  • A one-for-ten reverse stock split was effected on January 28, 2025.

Voting matters and shareholder proposals

  • Election of three Class II directors (Garo Armen, Barbara Ryan, John Holcomb) for three-year terms expiring at the 2029 annual meeting.

  • Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

  • Board recommends voting FOR all nominees and auditor ratification.

  • Shareholders may submit proposals for the 2027 annual meeting by December 30, 2026, following specific procedures.

Board of directors and corporate governance

  • Board consists of seven members divided into three classes, with annual elections for one class.

  • Majority of directors are independent; annual self-evaluations and performance assessments are conducted.

  • Three standing committees: Audit and Finance, Compensation, and Corporate Governance and Nominating; an Affiliate Transactions Committee addresses conflicts with Agenus.

  • Code of Ethics and Securities Trading Policy updated in 2023; independent directors meet in executive session.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more